Institutional investors purchased a net $668.0 thousand shares of TARO during the quarter ended December 2014. This may signal that the smart money is gaining interest in this company as the 12.51% of the shares outstanding that institutional investors hold is among the lowest in the Pharmaceuticals: Generic industry.